Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
12 hedge funds and large institutions have $152K invested in Baudax Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
20% more capital invested
Capital invested by funds: $127K → $152K (+$25K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$43K |
| 2 |
Jane Street
New York
|
+$26.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.22K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.61K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$55.8K |
| 2 |
JP Morgan Chase
New York
|
-$3K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.79K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Creative Planning
Overland Park,
Kansas
| $52.7K | +$43K | +45,001 | New |
|
|
2
Jane Street
New York
| $32K | +$26.1K | +27,342 | New |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $29.1K | – | – | – |
|
4
State Street
Boston,
Massachusetts
| $13.6K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $12.4K | +$8.61K | +9,010 | +582% |
|
|
6
UBS Group
Zurich,
Switzerland
| $11.3K | +$9.22K | +9,656 | New |
|
7
BlackRock
New York
| $932 | – | – | – |
|
|
8
Wells Fargo
San Francisco,
California
| $51 | +$39 | +41 | +1,367% |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $24 | – | – | – |
|
10
Group One Trading
Chicago,
Illinois
| $5 | – | – | – |
|
11
Morgan Stanley
New York
| $1 | – | – | – |
|
|
SN
12
Sittner & Nelson
Eugene,
Oregon
| $1 | – | – | – |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$55.8K | -32,812 | Closed |
|
|
14
JP Morgan Chase
New York
| – | -$3K | -1,511 | Closed |
|
|
15
Fidelity Investments
Boston,
Massachusetts
| – | -$1.79K | -1,056 | Closed |
|
BXRX Hedge Fund Activity: Q2 2023 in Review
12 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q2 2023, worth a combined $152K — up 20% from $127K a quarter earlier.
Fund positioning in BXRX was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Creative Planning, opening a new position worth an estimated $43K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $55.8K sold.
- 12 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $152K of Baudax Bio, Inc. Common Stock stock for Q2 2023, up 20% quarter-over-quarter.
- 3 funds opened new Baudax Bio, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q2 2023 was Creative Planning, an estimated $43K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q2 2023 was Susquehanna International Group, an estimated $55.8K sold.
Based on aggregated 13F filings for Q2 2023.